Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 12/20 | 0.48 |
| ▸ | PLK3 | Q9H4B4 | 6/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.43 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2274675 | 0.98 | PLK1 (0.46) | PLK1PLK3KDM4EMAPK1HSD17B10 | |
| SCHEMBL27716624 | 0.89 | PLK1 (0.47) | PLK1PLK3KDM4EMAPK1HSD17B10 | |
| SCHEMBL27716638 | 0.87 | HSD17B10 (0.46) | PLK1PLK3KDM4EMAPK1HSD17B10 | |
| SCHEMBL2273303 | 0.86 | NPC1 (0.43) | PLK1PLK3KDM4EMAPK1HSD17B10 | |
| SCHEMBL2272564 | 0.86 | ACLY (0.48) | HDAC1 | |
| SCHEMBL2272409 | 0.83 | PLK1 (0.63) | PLK1PLK3HDAC1LTC4SSLC16A3 | |
| SCHEMBL2275189 | 0.82 | MAPK1 (0.54) | KDM4EMAPK1HSD17B10 | |
| SCHEMBL2275549 | 0.81 | SLC16A3 (0.43) | PLK1KDM4ESLC16A3 | |
| SCHEMBL2270158 | 0.81 | MAPK1 (0.50) | KDM4EMAPK1HSD17B10HDAC1NR1H4 | |
| SCHEMBL2271236 | 0.80 | PLK1 (0.60) | PLK1PLK3HDAC1LTC4SMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999132-B2 | Anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| EP-1820795-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | MMP13, MMP26, MMP11 | PLK1 4227/4885PLK3 3893/4885KDM4E 1257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.